Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy
NCT ID: NCT00939315
Last Updated: 2016-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
51 participants
OBSERVATIONAL
2009-07-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients
NCT01579253
Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients
NCT01089868
FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
NCT01089244
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
NCT03370926
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas
NCT04766632
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To demonstrate if the multimodal approach, combining the morphological aspect of the MRI with the metabolic aspect of the tumor with magnetic resonance spectroscopy (MRS) and O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) or 18F\]-fluorocholine (FCH) PET/CTthe FCH allows to improve the location of a active metabolic tumor and its impact on the ideal choice of sampling biopsy.
* To underline the differences and similarities between MRS and 18F\]-fluorocholine PET / CT in the assessment of metabolism of the choline. To establish the diagnosis value of both methods, separately and in combination.
* To determine which examinations are useful and complementary for the diagnosis and the management of gliomes.
FET combined with MRS may be a powerful, widely applicable new method to improve the diagnosis of cerebral gliomas. The extent to which FCH and MRS provide similar information is not known precisely and this study will establish their respective diagnostic value in differentiating tumoral from non-tumoral tissue.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men of women
* Age \>18, no upper limit as long as a biopsy or intervention is foreseen
Exclusion Criteria
* Previous neurosurgical intervention (biopsy, shunt, etc.) or any other cerebral treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lionel Perrier Foundation (Montreux, Switzerland)
UNKNOWN
University of Lausanne Hospitals
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
John O. Prior
Professor and Head of Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John O Prior, PhD MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire Vaudois and University of Lausanne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Universitaire Vaudois
Lausanne, CH, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Swissmedic 2009DR3123
Identifier Type: OTHER
Identifier Source: secondary_id
196/08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.